Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Table 6 Costs, incremental costs and cost-effectiveness ratios* for ranibizumab treatment compared with no ranibizumab treatment for a 67-year old woman over a 10-year time horizon, under different treatment effectiveness and dosing scenarios.

Scenario	Cost			Cost per case of blindness prevented	Cost per blind-year prevented	Cost per QALY gained
	Ranibizumab treatment	No ranibizumab treatment	Difference
	$	$	$	$	$	$
Base-case scenario
Including caregiver costs
Ranibizumab cost
Wholesale price	205,800	238,300	-32,500	Dominant^†	Dominant	Dominant
Bevacizumab price	147,100	238,300	-91,100	Dominant	Dominant	Dominant
Excluding caregiver costs
Ranibizumab cost
Wholesale price	88,800	26,300	62,400	217,700	29,200	91,900
Bevacizumab price	30,100	26,300	3,800	13,200	1,800	5,600
Sustained-effect scenario
Including caregiver costs
Ranibizumab cost
Wholesale price	144,400	238,300	-93,800	Dominant	Dominant	Dominant
Bevacizumab price	125,500	238,300	-112,700	Dominant	Dominant	Dominant
Excluding caregiver costs
Ranibizumab cost
Wholesale price	42,200	26,300	15,900	41,100	6,400	20,300
Bevacizumab price	23,300	26,300	-3,000	Dominant	Dominant	Dominant
Non-sustained-effect scenario
Including caregiver costs
Ranibizumab cost
Wholesale price	209,800	238,300	-28,500	Dominant	Dominant	Dominant
Bevacizumab price	164,800	238,300	-73,500	Dominant	Dominant	Dominant
Excluding caregiver costs
Ranibizumab cost
Wholesale price	74,000	26,300	47,700	218,600	27,900	86,900
Bevacizumab price	29,100	26,300	2,700	12,500	1,600	5,000

*Costs are in 2004 U.S. dollars and were rounded.
Costs, blind-years and QALYs were discounted at 3% per annum
† Dominant: Ranibizumab treatment was more effective and cost less than the no ranibizumab strategy

ISSN: 1478-7547